Since 2019, three disease-specific therapies have been approved to treat patients with ATTR-CM. The first was Pfizer’s Vyndamax (tafamidis) in May 2019, which was approved for both wild type and ...

Background Amyloid transthyretin (ATTR) amyloidosis is a rare, life-threatening disease frequently manifesting with ...

The evaluation committee considered evidence submitted by Alnylam Pharmaceuticals, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the ...

After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470] ...

They found that about 1 in 8 people with a normal heart rhythm actually had a hidden problem called atrial electromechanical ...

Veterans Face Long Delays in ATTR-CM Diagnosis After HF Veterans face substantial delays in being diagnosed with transthyretin amyloid cardiomyopathy after a heart failure diagnosis, with most facing ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Fast Five Quiz: Castration-Resistant Prostate Cancer How much do you know about the presentation, workup, and treatment of castration-resistant prostate cancer and metastatic disease? Test your ...

"AMVUTTRA ® represents a major advance in the treatment of TTR amyloid cardiomyopathy, and the HELIOS-B trial clearly demonstrated its ability to significantly reduce cardiovascular events, slow ...

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please ...

The FDA has approved aficamten (Myqorzo; Cytokinetics), a cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). 1 ...